FiercePharmaOriginal article
{"a":[{"_":"Hansa lays groundwork for Nasdaq debut ahead of US kidney transplant drug verdict","$":{"href":"/pharma/hansa-lays-groundwork-nasdaq-debut-ahead-us-kidney-transplant-drug-verdict","hreflang":"en"}}]}
RegulatoryimlifidasePositive
AI Analysis
Summary
Hansa Biopharma is preparing for a potential Nasdaq listing ahead of an expected FDA decision on its kidney transplant drug imlifidase anticipated before year-end 2026.
Importance:6/10
Sentiment:
0.30
FDA decision pendingkidney transplantNasdaq listingimlifidase
Related Companies
Read the original article
Published by FiercePharma on August 24, 2026 2:27 PM